drugset / Trial / NCT05218915

Basal Plus GLP1-ra on Glycemic Variability in CKD

NCT05218915

Phase 4 Completed 95 enrolled Elaine Chow
RandomizedParallel-groupOpen-labelTreatment

Summary

To compare GLP-1 RA plus basal insulin (BGLP) versus basal-bolus (BB) insulin regimens on glycemic variability (GV) and time in range (TIR) in diabetes patients CKD stage 3-4

Timeline

Start
2022-01-28
Primary completion
2024-10-30
Completion
2024-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Dulaglutide Peptide Subcutaneous
Background insulin degludec Protein / enzyme biologic